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V-type proton (H+ ) ATPase (v-ATPase) is a multi-subunit proton pump that regulates pH homeostasis in all eukaryotic cells; in
neurons, v-ATPase plays additional and unique roles in synapse function. Through whole exome sequencing, we identiﬁed de novo
heterozygous mutations (p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn, p.Asp371Gly) in ATP6V1A, encoding the A subunit of v-
ATPase, in four patients with developmental encephalopathy with epilepsy. Early manifestations, observed in all patients, were
developmental delay and febrile seizures, evolving to encephalopathy with profound delay, hypotonic/dyskinetic quadriparesis and
intractable multiple seizure types in two patients (p.Pro27Arg, p.Asp100Tyr), and to moderate delay with milder epilepsy in the
other two (p.Asp349Asn, p.Asp371Gly). Modelling performed on the available prokaryotic and eukaryotic structures of v-ATPase
predicted p.Pro27Arg to perturb subunit interaction, p.Asp100Tyr to cause steric hindrance and destabilize protein folding,
p.Asp349Asn to affect the catalytic function and p.Asp371Gly to impair the rotation process, necessary for proton transport.
We addressed the impact of p.Asp349Asn and p.Asp100Tyr mutations on ATP6V1A expression and function by analysing
ATP6V1A-overexpressing HEK293T cells and patients’ lymphoblasts. The p.Asp100Tyr mutant was characterized by reduced
expression due to increased degradation. Conversely, no decrease in expression and clearance was observed for p.Asp349Asn. In
HEK293T cells overexpressing either pathogenic or control variants, p.Asp349Asn signiﬁcantly increased LysoTracker ﬂuores-
cence with no effects on EEA1 and LAMP1 expression. Conversely, p.Asp100Tyr decreased both LysoTracker ﬂuorescence and
LAMP1 levels, leaving EEA1 expression unaffected. Both mutations decreased v-ATPase recruitment to autophagosomes, with no
major impact on autophagy. Experiments performed on patients’ lymphoblasts using the LysoSensorTM probe revealed lower pH
of endocytic organelles for p.Asp349Asn and a reduced expression of LAMP1 with no effect on the pH for p.Asp100Tyr. These
data demonstrate gain of function for p.Asp349Asn characterized by an increased proton pumping in intracellular organelles, and
loss of function for p.Asp100Tyr with decreased expression of ATP6V1A and reduced levels of lysosomal markers. We expressed
p.Asp349Asn and p.Asp100Tyr in rat hippocampal neurons and conﬁrmed signiﬁcant and opposite effects in lysosomal labelling.
However, both mutations caused a similar defect in neurite elongation accompanied by loss of excitatory inputs, revealing that
altered lysosomal homeostasis markedly affects neurite development and synaptic connectivity. This study provides evidence that
de novo heterozygous ATP6V1A mutations cause a developmental encephalopathy with a pathomechanism that involves perturb-
ations of lysosomal homeostasis and neuronal connectivity, uncovering a novel role for v-ATPase in neuronal development.
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Introduction
V-type proton (H+) ATPase (v-ATPase) is a multimeric
complex that acts as an ATP-dependent proton pump.
V-ATPase is composed of a peripheral V1 domain that
hydrolyses ATP and an integral V0 domain that translo-
cates protons by a rotary mechanism. V-ATPase is
responsible for membrane trafﬁcking processes such as re-
ceptor-mediated endocytosis, intracellular trafﬁcking of
lysosomal enzymes, and acidiﬁcation of intracellular organ-
elles in all eukaryotic cells (Forgac, 2007; Cotter et al.,
2015). Despite the ubiquitous role in pH homeostasis and
intracellular signalling pathways, the v-ATPase complex is
expressed at high levels in neurons where it plays add-
itional and unique roles in neurotransmitter loading into
synaptic vesicles and in regulating synaptic transmission
(Morel and Poe¨a-Guyon, 2015; Bodzeta et al., 2017).
In humans, a redundant set of subunits is encoded by
22 autosomal genes, allowing the composition of diverse v-
ATPase complexes with speciﬁc properties and tissue
expression. Among these, seven have been associated with
human disease (Supplementary Table 1). Six subunits have
been related to recessive disorders, including distal renal
tubular acidosis and hearing loss (ATP6V1B1 and
ATP6V0A4) (Karet et al., 1999; Smith et al., 2000; Stover
et al., 2002), osteopetrosis with macrocephaly, progressive
deafness, blindness, hepatosplenomegaly, and severe anaemia
(ATP6V0A3) (Frattini et al., 2000; Kornak et al., 2000), and
cutis laxa, a systemic disease with severe neurological im-
pairment featuring structural brain abnormalities, profound
delay, and seizures (ATP6V0A2, ATP6V1E1 and ATP6V1A)
(Kornak et al., 2008; Fischer et al., 2012; Van Damme et al.,
2017). Two allelic dominant disorders, Zimmermann-
Laband syndrome type 2, featuring facial dysmorphisms
and intellectual disability (Kortum et al., 2015) and a form
of congenital deafness with anonyochia, have also been
described (ATP6V1B2) (Yuan et al., 2014).
Through whole exome sequencing of 1444 patients with
developmental encephalopathies and epilepsy, we identiﬁed
in four patients heterozygous de novo missense mutations
in ATP6V1A (p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn,
p.Asp371Gly), all involving highly evolutionarily conserved
residues in functionally relevant regions of the molecule.
Functional analysis conducted for the p.Asp100Tyr and
p.Asp349Asn mutations demonstrated a loss-of-function
mechanism involving increased ATPase degradation and
lysosomal defects for the former, and a gain-of-function
mechanism consisting of increased acidiﬁcation of intracel-
lular organelles for the latter. In neurons, both ATP6V1A
mutants caused a defect in neurite elongation, accompanied
by a signiﬁcant loss of excitatory synapses, suggesting a
crucial and unexplored role of v-ATPase in neuronal devel-
opment and synapse formation. We provide evidence that
de novo heterozygous ATP6V1A mutations cause a devel-
opmental encephalopathy with epilepsy with a pathome-
chanism that involves the effects of v-ATPase in
lysosomal homeostasis and neuronal connectivity. This
study also demonstrates that ATP6V1A mutations can be
disease causing at the heterozygous state, although previ-
ously described biallelic phenotypes are more severe.
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Patients and methods
Patients
Exome studies were conducted in three cohorts, including pa-
tients of different ethnicities (Supplementary Table 2A), with
developmental delay/intellectual disability and epilepsy of pre-
sumed genetic origin. The overall series consisted of 1444 pro-
bands, most of whom were part of a trios study. Patients were
assigned to eight speciﬁc epileptic encephalopathy syndromes,
plus a ninth subgroup of ‘unclassiﬁed’ epileptic encephalopa-
thies with mixed seizure disorders that could not be assigned
to a speciﬁc syndrome (Supplementary Table 2B). All four
patients with ATP6V1A mutations belonged to the latter
subgroup.
All participants to the study had signed an informed consent
for research whole exome sequencing studies. The study was
approved by the Paediatric Ethic Committee of the Tuscany
Region, in the context of the DESIRE project (Seventh
Framework Programme FP7; grant agreement n 602531).
Whole exome sequencing
In 900 patients, whole exome sequencing was performed with
the SureSelectXT Human All Exon v5 or v6 (Agilent
Technologies). Captured libraries were sequenced using
Illumina Hiseq 2500 (Illumina) with 101-base paired-end
reads. Exome data processing, variant calling, and variant an-
notation were performed as previously described (Saitsu et al.,
2013). In singleton probands exhibiting de novo mutations,
parentage was conﬁrmed by microsatellite analysis, as previ-
ously described (Saitsu et al., 2013). In 494 patients, whole
exome sequencing was performed and analysed as previously
described (Narayanan et al., 2015). In 50 additional patients,
exons were captured from fragmented genomic DNA samples
using the SureSelect Human All Exon v4 (Agilent
Technologies), and paired-end 90-base massively parallel
sequencing was carried out on an Illumina HiSeq 2000, ac-
cording to the manufacturer’s protocols (Illumina). In the latter
group, bioinformatics analysis was carried out using an in-
house developed pipeline. Sequencing reads passing quality ﬁl-
tering were aligned to the human reference genome (hg19)
with Burrows-Wheeler Aligner (BWA) (Li and Durbin,
2010). The Genome Analysis Toolkit (GATK) (McKenna
et al., 2010) was used for base quality score recalibration,
indel realignment, duplicate removal, and to perform SNP
and INDEL discovery and genotyping across all samples sim-
ultaneously using variant quality score recalibration according
to GATK Best Practices recommendations (DePristo et al.,
2011; Van der Auwera et al., 2013). For annotating and ﬁl-
tering data, the SNPeff program was used (Cingolani et al.,
2012). The de novo variants were called using the
DeNovoGear tool with a 0.8 threshold at the posterior prob-
ability of the most likely de novo genotype conﬁguration
(Ramu et al., 2013). All samples had a mean depth of target
region covered at 112 and 497% of bases in the consensus
coding sequences covered by at least 20 reads. We excluded
variants with minor allele frequency (MAF) 41% in either the
1000 Genomes Project (1000g) or the Exome Aggregation
Consortium (ExAC v0.3) databases.
In patients carrying ATP6V1A variants, we excluded de
novo or recessive (MAF51%) variants in the well-established
genes for epileptic encephalopathies (listed in Supplementary
Table 3) and submitted for validation and segregation testing
by Sanger sequencing of candidate de novo variants that were
predicted to alter protein function (non-synonymous, stop-
gain, stop-loss, frameshift, and splice-junction mutations).
We evaluated whether the ATP6V1A human protein-coding
gene is likely to harbour disease-causing mutations using dif-
ferent gene-level prediction tools including the ExAC (Exome
Aggregation Consortium) constraint metrics (Lek et al., 2016),
the residual variation intolerance score (RVIS; based on ExAC
v2 release 2.0) (Petrovski et al., 2013) and the gene damage
index (GDI) (Itan et al., 2015). Furthermore, to improve the
use of existing variant-level methods such as the Combined
Annotation Dependent Depletion (CADD) score (Kircher
et al., 2014) and test the four missense substitutions we iden-
tiﬁed in ATP6V1A, we also used the mutation signiﬁcance cut-
off (MSC) server (Itan et al., 2016), a quantitative approach
that provides gene-level and gene-speciﬁc phenotypic impact
cut-off values.
We evaluated mutations’ pathogenicity for the four
ATP6V1A variants through in silico prediction using the
dbNSFP database (v3.0a), which provides functional predic-
tion scores on more than 20 different algorithms (https://
sites.google.com/site/jpopgen/dbNSFP). To assess the effects
of the four missense ATP6V1A substitutions, we used both
the dbNSFP ensemble rank scores MetaSVM and MetaLR
(Liu et al., 2016). In addition, we used the scores obtained
from Revel (Ioannidis et al., 2016), M-CAP (Jagadeesh et al.,
2016) and Eigen (Ionita-Laza et al., 2016), three different bio-
informatics tools to evaluate the pathogenicity of rare variants.
We performed conservation analysis across species (ortholo-
gous sequences) using a multiple sequence alignment (MSA) of
the ATP6V1A protein sequence. The MSA (MUSCLE algo-
rithm) and the sequence logo consensus were generated by
the Jalview software (http://www.jalview.org). Residues were
coloured according to their physicochemical properties
(Zappo colour scheme).
To evaluate if de novo ATP6V1A variants had ever been
reported, either in affected individuals or controls, we interro-
gated the denovo-db database (Turner et al., 2017).
ATP6V1A gene de novo mutation
enrichment analysis
To assess whether in the 1444 probands cohort the ATP6V1A
gene was enriched in missense de novo mutations, we used the
freely available R package DenovolyzeR (Ware et al., 2015)
and gene-speciﬁc mutation rates originally reported by
Samocha et al. (2014). The ATP6V1A de novo gene-speciﬁc
P-value calculated by DenovolyzeR for missense variants was
corrected for multiple testing (Bonferroni correction), accord-
ing to the 19 618 genes for which mutation rates are available,
and the number of tests (one test for the missense class). The
genome-wide Bonferroni corrected P-value threshold at
a = 0.05 for one test was 2.55  106 [0.05/(1  19 168)].
We carried out the ATP6V1A de novo mutation enrichment
analysis in the overall cohort without any stratiﬁcation using
the RStudio software (rstudio.com).
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To rule out that the four variants could have arisen by
chance, we performed the chi-squared test with Yates correc-
tion for a 2  2 contingency table (patients carrying the vari-
ants/mutation negative patients versus controls carrying the
variants/mutation negative controls) using the QuickCalcs
tool (graphpad.com/quickcalcs/contingency1.cfm). For each
variant, we carried out the test on exome data of our cohort
and the Genome Aggregation Database (gnomAD) cohorts,
both at large and through ethnicity-matched analysis.
Structural modelling
We searched the crystal structure homologous to human
ATP6V1A using the protein homology/analogy recognition
engine, Phyre2 (Kelley et al., 2015). We calculated the free
energy change upon the Asp85Tyr mutation with the FoldX
software (foldxsuite.crg.eu) using the crystal structure of the
V1 domain from Enterococcus hirae v-ATPase in a nucleotide-
bound state (PDB code 3VR6). The molecular structures were
drawn using PyMOL (Schro¨dinger, New York, NY). Using the
same Phyre2 server, we also obtained the alignment of human
ATP6V1A and Saccharomyces cerevisiae A subunit primary
sequences. The homology model was created using I-TASSER
(Roy et al., 2010), with the A subunit of S. cerevisiae v-ATPase
(PDB code 3J9T) as template.
ATP6V1A constructs
We synthesized wild-type and mutant (p.Asp100Tyr and
p.Asp349Asn) human ATP6V1A cDNAs in vitro and cloned
in pLVX-IRES-mCherry vector by Biomatik. We performed
Sanger sequencing of all constructs to check the correct inserts
orientation and validate their sequence.
Cell culture and transfection
Human embryonic kidney-derived 293T (HEK) cells were
maintained at 37C in a humidiﬁed 5% CO2 incubator in
DMEM (Life Technologies) supplemented with 10% FBS,
2mM L-glutamine and 1% Penicillin-Streptomycin. Cells
were transfected with Lipofectamine 2000 (Life Technologies)
according to the manufacturer’s instructions. HEK cells were
starved by medium withdrawal for 2 h. Lymphoblatsts were
prepared by infecting lymphocytes obtained from patients
and their parents with the Epstein-Barr virus (EBV) in vitro
using standard protocols and maintained in RPMI 20% foetal
bovine serum (FBS), 1mM L-glutamine and 10mM D-glucose.
Primary cortical neurons were prepared from embryonic Day
18 brains of Sprague Dawley rats as previously described
(Verstegen et al., 2014). Neurons were transfected using
Lipofectamine 2000 at 7 or 14 days in vitro (DIV) and ana-
lysed 3 days after transfection.
Western blotting
Protein lysates from HEK, lymphoblast and neuronal cultures
were extracted in lysis buffer [50 mM Tris (pH 7.5), 150mM
NaCl, 0.1% SDS, 1% Nonidet P40, 0.2mM phenylmethylsul-
fonyl ﬂuoride, 2mg/ml pepstatin, and 1mg/ml leupeptin] and
then separated by SDS-PAGE and assayed by immunoblotting
with the following primary antibodies: anti-ATP6V1A
(1:1000; #ab137574, Abcam), anti-ATP6V1B2 (1:2000;
#ab73404, Abcam), anti-LAMP1 (1:1000; #ab24170,
Abcam), anti-EEA1 (1:5000; #610457, BD Bioscience), LC3B
(1:1000; #7543, Sigma-Aldrich), p62 (1:1000, #P0067, Sigma-
Aldrich), anti-GAPDH (1/1000; #SC-25778, Santa Cruz
Biotechnology), anti-VAMP2 (1:1000; #104202; Synaptic
Systems); anti-V-GLUT1 (1:1000; #135304, Synaptic
Systems) anti-PSD95 (1:1000; #SC-32290, Santa Cruz
Biotechnology).
Degradation assay
HEK cells were transfected with ATP6V1A wild-type,
ATP6V1A Asp349Asn or ATP6V1A Asp100Tyr and treated
with 10 mg/ml of cycloheximide (C4859, Sigma-Aldrich) 24 h
after transfection. Cells were lysed at different times after
cycloheximide addition and analysed by western blotting.
Protein level is expressed with respect to ATP6V1A content
in the cells collected at time zero and treated with vehicle
(DMSO).
Immunocytochemistry and
fluorescence microscopy
Transfected primary cortical neurons or HEK cells were ﬁxed
in 4% paraformaldehyde in phosphate-buffered saline (PBS),
permeabilized in 0.1% TritonTM X-100, blocked with 2%
FBS/0.05% Tween-20 in PBS and incubated with the various
antibodies in blocking solution. Samples were mounted in
ProLong Gold antifade reagent with DAPI (#P36935,
Thermo-Fisher Scientiﬁc). Capture of confocal images was per-
formed using a laser scanning confocal microscope (SP5, Leica)
with a 40 or 63 oil-immersion objective. For LAMP1
(1:200, #L1418 Sigma-Aldrich) and EEA1 (1:500; #610457,
BD Bioscience), ATP6V1B2 (1:200, #SAB1405501 Sigma-
Aldrich) and LC3B (1:200, #2775 Cell Signalling) labelling,
each image consisted of a stack of images taken through the
z-plane of the cell. The co-localization of ATP6V1B2 and
LC3B signals was analysed using the ImageJ intensity correl-
ation analysis plugin to calculate Pearson’s correlation coefﬁ-
cient. For LysoTracker Deep Red (Molecular Probes/Life
Technologies) experiments, HEK cells were incubated with
200 nM LysoTracker for 1 h, whereas neurons were incu-
bated with 50 nM LysoTracker for 30min, at 37C in culture
medium, immediately ﬁxed and analysed within 12 h. Images
were taken at either epiﬂuorescence (Olympus 1X81) or con-
focal (SP5, Leica) microscope in a single plane not to fade the
ﬂuorescent signal. Settings were kept the same for all acquisi-
tions within each experiment.
Measurement of endo-lysosomal pH
Endo-lysosomal pH was measured using a ratiometric pH in-
dicator dye, LysoSensorTM Yellow/Blue dextran (Molecular
Probes/Life Technologies), a dual excitation dye that allows
pH measurement in endocytic organelles independently of
dye concentration. Lymphoblasts (4  106) were incubated
for 3 h at 37C with 0.5mg/ml of LysoSensorTM Yellow/Blue
dextran in culture medium. Cells were divided into ﬁve sam-
ples, four to perform the calibration curve and one for the
measurements. To obtain a pH calibration curve, cells were
resuspended with MES calibration buffer solution
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(5mM NaCl, 115mM KCl, 1.2mM MgSO4 and 25mM MES,
pH ranging from 3.7 to 7.6) containing 10 mM monensin
(Sigma-Aldrich) and 10 mM nigericin (Sigma-Aldrich). For the
pH measures, cells were resuspended in MES calibration buffer
solution pH 7.7 in the absence of ionophores. Emission scans
were collected at 450 nm and 528nm with the Luminescence
Spectrometer LS 50 (Perkin Elmer), using excitation at 360 nm
and emission/excitation bandwidths set to 4 nm. Calibration
data (ratio 450/528) were ﬁtted to a linear regression with
the software GraphPad Prism5 and the sample ratios converted
into absolute pH values by interpolation in the calibration
function.
Sholl analysis
Neurons were plated at low density (80 cells/mm2), transfected
at 7 DIV and analysed at 10 DIV. For analysis, neurons were
ﬁxed in 4% PFA, in PBS and decorated with bIII tubulin anti-
body (1:1000, #MMS-435P Covance) followed by Alexa
Fluor 488 secondary antibody to unequivocally distinguish
neuronal cells. The extent of neurite arborization was evalu-
ated using Sholl analysis as previously described (Falace et al.,
2010). Concentric circles with radii increasing at regular 10-
mm steps were centred to the cell body and the number of
intersections was automatically evaluated with the ImageJ/
Sholl analysis plug-in.
Synapse quantification
Neurons, plated at low density as described above, were either
transfected at 14 DIV and analysed at 17 DIV or treated at 17
DIV with 200 nM leupeptin for 3 h (#EI8, MerckMillipore;
Goo et al., 2017). To measure excitatory synapses, neurons
were labelled with anti-V-GLUT1 (1/500, #135304; Synaptic
Systems) and anti-Homer1 (1/200, #160011; Synaptic Systems)
antibodies. Confocal images were acquired with a laser scan-
ning confocal microscope (SP5 Upright, Leica) with a 40 oil-
immersion objective. Each image consisted of a stack of images
taken through the z-plane of the cell. Confocal microscope
settings were kept the same for all scans in each experiment.
The co-localization analysis was performed by evaluating the
labelling of the VGLUT1/Homer1 synaptic protein couples.
Co-localization puncta with areas of 0.1–2 mm2 were con-
sidered bona ﬁde synaptic boutons. Synaptic boutons along
Cherry-positive neurites were manually counted on 30 mm
puncta starting from the cell body.
Results
Identification of ATP6V1A mutations
Trio-based whole exome sequencing studies revealed de
novo mutations in ATP6V1A (MIM 607027; RefSeq ac-
cession number NM_001690.3), encoding the ATPase H+
transporting V1 subunit A in three patients [Patient 1:
c.298G4T (p.Asp100Tyr); Patient 2: c.1045G4A
(p.Asp349Asn); and Patient 4: c.80C4G (p.Pro27Arg)].
A subsequent search for ATP6V1A variants in whole
exome sequencing data obtained from singleton patients,
identiﬁed an additional patient carrying a de novo
heterozygous ATP6V1A variant [Patient 3: c.1112A4G
(p.Asp371Gly)]. Patients 1–3 were identiﬁed via an ongoing
collaboration matching exome data generated in Europe by
the DESIRE project on rare developmental/epileptic ence-
phalopathies (http://epilepsydesireproject.eu) with those of
a comparable cohort in Japan. Patient 4 was subsequently
identiﬁed through DESIRE dissemination activities, after
preliminary data on the ﬁrst three patients were made
available in the project website. We also screened for
ATP6V1A inherited variants with a frequency 51% in
the 1000 Genomes Project (1000g) or in the Exome
Aggregation Consortium (ExAC) databases, both in cases
of homozygous recessive or compound heterozygous state.
None of the de novo ATP6V1A identiﬁed mutations was
observed in the 1000g, ExAC, gnomAD or dbSNP (build
147) databases. We conﬁrmed the mutations and their de
novo nature on genomic DNA of probands and parents by
Sanger sequencing. Patient 3 parentage was conﬁrmed
using 12 microsatellite markers.
All four highly functionally relevant de novo mutations
caused missense substitutions at evolutionarily conserved
amino acid positions (Fig. 1) and were predicted to be dama-
ging by in silico methods (Supplementary Table 4A). ExAC
constraint metrics indicated that ATP6V1A has fewer vari-
ants than expected and is intolerant both to loss-of-function
(pLI = 0.99) and missense variants (Z-score = 3.03). The
RVIS (RVIS score 0.7; RVIS percentile 20.93%) and the
GDI (GDI score 22.7; GDI_Phred 0.76) scores also highlight
ATP6V1A intolerance to variations. Finally, the MSC
damage prediction (99% conﬁdence interval) tool highlights
the highly damaging impact the p.Pro27Arg, p.Asp100Tyr,
p.Asp349Asn, and p.Asp371Gly substitutions have on the
ATP6V1A protein, according to the MSC CADD corrected
scores (Supplementary Table 4B).
To explore pathogenicity of the four variants further, we
performed gene-speciﬁc de novo mutation enrichment ana-
lysis and a variant-speciﬁc chi-squared test with Yates cor-
rection for a 2  2 contingency table. The ATP6V1A
missense de novo mutations enrichment analysis performed
with DenovolyzeR (n = 1444, de novo mutations
observed = 4, de novo mutations expected = 0.1, enrich-
ment 79) reached genome-wide statistical signiﬁcance
(P-value of 2.63  107; Bonferroni correct threshold P-
value 2.55  106). All four variants reached signiﬁcant
values (P5 0.0001) in the chi-squared test performed
using the 123 136 gnomAD exomes as control
(Supplementary Table 5A). Performing the same analysis
matching the four mutations versus ethnically matched sub-
populations, all mutations maintained signiﬁcant values
(Supplementary Table 5B–E). These data suggest that the
ATP6V1A mutations did not occur by chance in the cohort
studied.
The denovo-db returned only ﬁve de novo hits (three
intronic and two missense substitutions) in ATP6V1A.
The two missense substitutions were p.Asp11Asn, identiﬁed
in a male with autism spectrum disorder (Iossifov et al.,
2014), and p.Pro249Arg identiﬁed in another male with a
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severe developmental disorder (McRae et al., 2017). These
two missense substitutions, however, have not been sub-
jected to orthogonal validation and should therefore be
considered as ‘potential’ de novo variants. These data fur-
ther highlight how rare de novo mutations are in the
ATP6V1A gene.
Clinical findings
Clinical, EEG and MRI ﬁndings observed in the four pa-
tients are summarized in Table 1 and presented in detail in
the Supplementary material. In brief, early manifestations,
observed in all patients, were developmental delay and fe-
brile seizures, evolving in two patients to encephalopathy
with profound delay, hypotonic/dyskinetic quadriparesis,
intractable multiple seizure types and severe diffuse epilepti-
form EEG abnormalities (Patients 1 and 4) and to moderate
delay with milder epilepsy and focal/multifocal EEG
abnormalities in the other two (Patients 2 and 3).
Structural consideration of the
v-ATPase mutations
We mapped the mutation sites of human ATP6V1A onto
the crystal structure of the V1 domain from a prokaryotic
homologue, E. hirae v-ATPase, in a nucleotide-bound
state (PDB code 3VR6) (Arai et al., 2013). All the identiﬁed
mutations fall into the A subunit of the V1 domain
(Fig. 2A).
Pro12 (Pro27 in human ATP6V1A) resides in the type I
b-turn that is a part of the interaction interface between
subunits A and B. Since the substitution of a proline residue
with an arginine residue affects the main-chain conform-
ation of the b-turn, the mutation may perturb the A–B
interaction (Fig. 2A and B).
Asp85 (Asp100 in human ATP6V1A) makes a hydrogen
bond with Arg89, a guanidium group that makes van der
Waals contacts with adjacent hydrophobic side chains
(Fig. 2B). As a result, the side chain of Asp85 is closely
surrounded by hydrophobic residues, and its replacement
with a bulkier tyrosine residue quite likely causes steric
hindrance and destabilizes the protein folding. This is
supported by the FoldX calculation, which predicted a sig-
niﬁcant increase in free energy (about 13 kcal/mol) upon
the Asp85Tyr mutation.
Asp329 (Asp349 in human ATP6V1A) is located near a
nucleotide-binding site (Fig. 2B) and its side chain is
involved in water-mediated coordination with a magnesium
ion, which plays a critical role in the ATPase activity
(Fig. 2B). Thus, the Asp329Asn mutation possibly impairs
the catalytic function.
Asp351 (Asp371 in human ATP6V1A) is located at the
interface among A, B and D subunits (Fig. 2A). The D
subunit rotates within the A3B3 core along with the ATP
hydrolysis, and thus the rotation process may be affected
by the Asp351Gly mutation. The mutation sites were also
mapped on the cryo-EM structure of the human homo-
logue v-ATPase from the eukaryotic S. cerevisiae (rota-
tional state 1, PDB code 3J9T) (Zhao et al., 2015). As
shown in Fig. 2B, the mapped mutation sites in the S.
cerevisiae structure overlap with those of the E. hirae, sug-
gesting that the predicted impact of the mutations on the
prokaryotic structure is also valid for the eukaryotic
orthologues.
Finally, we generated a homology model of human
ATP6V1A (Supplementary Fig. 1) using S. cerevisiae A sub-
unit as template, obtaining a high-conﬁdence result (C-
score 88% and TM-score 87%). The resulting structure
shows a fold similar to the template (cf. Supplementary
Fig. 1 and 2B), and the mutation sites are in the same
locations of the E. hirae and S. cerevisiae structures.
Effects of ATP6V1A mutations on
protein expression and stability
We addressed the impact of p.Asp349Asn and
p.Asp100Tyr mutations on the ATP6V1A expression and
stability by analysing HEK cells overexpressing ATP6V1A.
Cells were transfected with vectors driving the expression
of the wild-type or mutant variants in association with a
Cherry ﬂuorescent tag for identiﬁcation. Immunocytochem-
istry of transfected cells coupled with quantitative western
blot analysis showed a decreased expression of both
ATP6V1A mutants that reached signiﬁcance only for the
Figure 1 Multiple sequence alignment and sequences logo. Multiple sequence alignment between human ATP6V1A and orthologous
sequences. Residues were coloured according to their physico-chemical properties (Zappo colour scheme). Residues affected by the missense
substitutions are indicated by black arrows.
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p.Asp100Tyr variant, and no overt subcellular mislocaliza-
tion of both p.Asp100Tyr and p.Asp349Asn mutants with
respect to wild-type ATP6V1A (Fig. 3A and B). The expres-
sion of the molecular partner, ATP6V1B2, was not modi-
ﬁed either by p.Asp100Tyr or p.Asp349Asn mutation
(Fig. 3B). To investigate the stability of ATP6V1A protein,
we performed a degradation assay by treating transfected
HEK cells with the protein synthesis inhibitor cyclohexi-
mide for various times. Compared to the wild-type isoform,
both mutant ATP6V1A isoforms were less stable, although
degradation was signiﬁcantly increased only for the
p.Asp100Tyr variant (Fig. 3C).
We next asked whether these ﬁndings could also be
observed in patients’ cells. To this end, we analysed the
expression of endogenous ATP6V1A protein in patients’
lymphoblasts and compared it with the respective healthy
parents’ cells (Fig. 3D and E). While the expression of
ATP6V1A and ATP6V1B2 was not modiﬁed in
Asp349Asn proband’s cells with respect to his healthy
mother’s cells, a signiﬁcant decrease of ATP6V1A, but
not ATP6V1B2, expression was observed in Asp100Tyr
proband’s cells. These data are in full agreement with the
structural analysis prediction of a folding defect in the
p.Asp100Tyr mutant (Fig. 2A) that may enhance its
degradation.
ATP6V1A mutations result in
lysosomal abnormalities
To examine the impact of the p.Asp349Asn and
p.Asp100Tyr mutations in the regulation of pH homeosta-
sis, we used the LysoTracker probe to qualitatively evalu-
ate intracellular acidic organelles in HEK cells
overexpressing either pathogenic or wild-type ATP6V1A
variants. Interestingly, the p.Asp349Asn mutant increased,
while the p.Asp100Tyr mutant decreased, LysoTracker
ﬂuorescence intensity (Fig. 4A). The LysoTracker signal
monitors both the actual pH of acidic organelles, namely
endosomal and lysosomal compartments, and their relative
abundance within the cell. Thus, we analysed in parallel the
expression of the endosomal and lysosomal markers, EEA1
and LAMP1, respectively. Whereas EEA1 expression was
unaltered in HEK cells expressing wild-type ATP6V1A or
either pathogenic variants, the p.Asp100Tyr mutant was
associated with a signiﬁcant decrease of LAMP1 expression
Table 1 Summary of clinical features in four patients carrying ATP6V1A mutations
Patient
1 2 3 4
Origin/sex Caucasian/F Asian/M Caucasian/F Latino/M
Age at follow-up 14 years 8 years 8 years 11 years
ATP6V1A mutation c.298G4T (p.Asp100Tyr) de
novo
c.1045G4A (p.Asp349Asn)
de novo
c.1112A4G (p.Asp371Gly)
de novo
c.80C4G (p.Pro27Arg) de
novo
Clinical diagnosis Infantile onset epileptic
encephalopathy
ID/epilepsy ID/epilepsy Infantile onset epileptic
encephalopathy
Head circumference At birth: 32 cm = 3rd %ile
(1.9 SD); at 12 years:
44.5 cm4 1st %ile (7
SD): microcephaly
At birth: 33 cm = 10th %ile
(1.2 SD)
Unknown At 12 months:
43.5 cm = 1st %ile (2.2
SD); at 11 years:
49 cm4 1st %ile (3.2
SD): microcephaly
Age/symptoms at first
clinical presentation
11 months, hypotonia, devel-
opmental delay, seizures
1 month, developmental
delay, jerky movement
2 years 6 months, develop-
mental delay, seizures
7 months, hypotonia, de-
velopmental delay
Epilepsy + + + +
Age at seizure onset 11 months 2 years 10 months 2 years 6 months 11 months
Seizures types Convulsive seizures during
fever at onset, then infantile
spasms, tonic, focal clonic,
focal occipital
Convulsive seizures during
fever at onset, then focal
occipital
Convulsive seizures during
fever at onset, then gener-
alized tonic-clonic
Convulsive seizures during
fever at onset, then
spasms, tonic, clonic and
myoclonic
Interictal EEG Slow background, diffuse and
multifocal epileptiform
discharges
Posteriorly dominant, multi-
focal epileptiform
discharges
Anteriorly predominant
multifocal epileptiform
discharges
Slow background, diffuse
and multifocal epilepti-
form discharges
Brain MRI Hypomyelination, mild brain
and cerebellar atrophy
Normal at 7 years Normal at 7 years Mild atrophy at 1 years
5 months and 3 years
7 months
Clinical phenotype
at last follow-up
Profound delay, non-verbal,
no visual fixation, hypo-
tonic/dyskinetic quadripar-
esis, non-ambulatory, early
puberty (9 years).
Moderate ID (FSDQ: 53),
poor language, headache,
amelogenesis imperfecta
diagnosed at 3 years, optic
atrophy
Moderate ID, poor language,
mild dysmorphic features
(wide forehead, deep set
eyes, beaked nose), behav-
ioural abnormalities with
autistic traits, wide based
gait, hypotonia
Profound delay, non-verbal,
no visual fixation, colo-
boma of the iris, hypo-
tonic/dyskinetic quadri-
paresis, non-ambulatory
F = female; FSDQ = full scale developmental quotient; ID = intellectual disability; M = male; N/A = not available.
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evaluated by both single cell immunocytochemistry
(Fig. 4B) and western blotting (Supplementary Fig. 2A).
The data suggest that the p.Asp349Asn mutant exacerbates
the acidic pH of intracellular organelles, while the
p.Asp100Tyr mutant leads to a decreased expression of
LAMP1-positive lysosomal structures. Lysosomes fuse
with phagosomal and autophagosomal structures to gener-
ate autolysosomes and v-ATPase also acidiﬁes autolysoso-
mal organelles. We therefore investigated whether
pathogenic ATP6V1A variants affect v-ATPase transloca-
tion to LC3-positive phagosomal structures. To this aim,
we measured the co-localization between the v-ATPase sub-
unit ATP6V1B2 and LC3 in HEK cells expressing wild-type
ATP6V1A or either pathogenic variant. Both p.Asp100Tyr
and p.Asp349Asn resulted in a decreased co-localization
coefﬁcient with respect to wild-type ATP6V1A (Fig. 4C).
However, the v-ATPase translocation induced by cell star-
vation was slightly impaired by p.Asp100Tyr and substan-
tially unaffected by p.Asp349Asn (Fig. 4C). No signiﬁcant
changes in LC3II/LC3I ratio and p62 accumulation were
observed in both experimental groups (Supplementary
Fig. 2B). These data suggest a signiﬁcant impact of both
mutations on the recruitment of the v-ATPase to LC3-posi-
tive autolysosomal structures, with slightly impaired autop-
hagic ﬂux only for Asp100Tyr.
To verify whether altered lysosomal pH and levels of
lysosomal markers were also present in patients, we sub-
jected patients’ lymphoblasts to the same analysis.
Experiments using the ratiometric pH probe LysoSensorTM
Yellow/Blue dextran, revealed a signiﬁcant reduction in
endocytic organelle pH in the Asp349Asn patient’s lympho-
blasts when compared to his healthy mother’s lymphoblasts,
in the absence of any change in the expression of LAMP1
and EEA1 (Fig. 5). Conversely, while the pH of endocytic
organelles was not modiﬁed in the Asp100Tyr patient’s
lymphoblasts, a signiﬁcant reduction in LAMP1 expression
was observed (Fig. 5). Taken together, these data suggest
a gain-of-function effect for the p.Asp349Asn mutation,
characterized by an increased proton pumping into intra-
cellular organelles, and a loss-of-function effect for the
Figure 2 Structural mapping of the missense mutations in the V-ATPase. (A) Left: Crystal structure of the V1 domain from E. hirae
v-ATPase in a nucleotide-bound state (PDB code 3VR6), viewed from the extracellular side (top) and the membrane plane (bottom), shown as the
sphere representation. The A, B, D and F subunits are coloured in cyan, green, violet and brown, respectively, and residues at the mutation sites
are coloured in red. The non-hydrolyzable ATP analogue ANP (phosphoaminophosphonic acid-adenylate ester) is depicted as orange sticks. Right:
Magnified views of the mutation sites presented in the ribbon model. Pro12 and Asp85 are depicted as red sticks, and Arg89, which makes a salt
bridge with Asp85, is shown as sticks with translucent spheres. Some side chains of hydrophobic residues around Arg89 are shown as translucent
spheres, and magnesium ion and its coordinated water molecules are depicted as a purple sphere and small grey dots, respectively. Black dotted
lines indicate hydrogen bonds. Amino acid numbers in parentheses correspond to those of human ATP6V1A. (B) Crystal structures of the A
subunit from E. hirae (orange) and the cryo-EM structure of the A subunit from S. cerevisiae (cyan, PDB code 3J9T) V-ATPase. Mutation sites are
shown as spheres and coloured in red for S. cerevisiae and blue for E. hirae.
8 | BRAIN 2018: Page 8 of 16 A. Fassio et al.
Downloaded from https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awy092/4969933
by guest
on 14 April 2018
Figure 3 Impact of ATP6V1A mutations on protein expression and stability. (A) Representative images of HEK cells transfected with
vectors coding wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) variants. ATP6V1A immu-
nolabelling, DAPI nuclear stain and Cherry reporter fluorescence are shown. Scale bar = 10 mm. (B) Representative western blot (left) from HEK
cells transfected as above and lysed 24 h after transfection. ATP6V1A and ATP6V1B2 intensities were quantified by densitometric analysis with
respect to GAPDH intensity (right). Data are means  standard error of the mean (SEM) from five independent experiments. *P5 0.05 versus
wild-type; Kruskall-Wallis/Dunn’s tests. (C) Left: Representative western blots of HEK cell lysates stained with anti-ATP6V1A antibody and anti-
GADPH as loading control. Cells were transfected with wild-type, Asp349Asn or Asp100Tyr ATP6V1A variants and incubated with cycloheximide
for 2, 4, 8, 24 h or vehicle (DMSO; 24 h) as a control (–). Right: Densitometric analysis of ATP6V1A intensity with respect to GADPH expressed in
percent of control samples without cycloheximide. Data are means  SEM from four independent experiments. The areas under the respective
curves were compared using the Kruskal-Wallis/Dunn’s tests. *P5 0.05 versus wild-type. (D) Representative western blot from lymphoblast
lysates (30mg) of patient affected by the Asp349Asn mutation (proband) and the healthy mother. (E) Representative western blot from
lymphoblast lysates (30mg) of patient affected by the Asp100Tyr mutation (proband) and the healthy mother. In D and E, ATP6V1A and
ATP6V1B2 intensity were quantified by densitometric analysis with respect to GADPH. Data are means  SEM from four independent experi-
ments. *P5 0.05; Mann Whitney U-test.
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Figure 4 Effects of ATP6V1A mutations on endo-lysosomal markers and v-ATPase recruitment to autophagosomes.
(A) Left: Representative images of HEK cells transfected with wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr
ATP6V1A (Asp100Tyr) variants and incubated with LysoTracker (200 nM, 1 h). Right: LysoTracker fluorescence intensity was quantified in 38
(wild-type), 41 (Asp349Asn) and 45 (Asp100Tyr) cells from three independent experiments. Individual data and means  SEM are shown.
*P5 0.05, ****P5 0.0001 versus wild-type; Kruskall-Wallis/Dunn’s tests. (B) Representative images and densitometric quantification from HEK
cells transfected as above and immunolabelled with LAMP1 (left) or EEA1 (right). Histograms show quantification of signal intensity. Data are
means  SEM of 24–33 cells per experimental condition, from three independent experiments. **P5 0.001 versus wild-type Kruskall-Wallis/
Dunn’s tests. (C) Representative images from HEK cells transfected as above and immunolabelled with ATP6V1B2 and LC3B under control
conditions or after starvation for 2 h. Graph shows the quantification of ATP6V1B2 and LC3B co-localization using ImageJ software to determine
the Pearson’s correlation coefficient. Data are means  SEM of 30 cells per experimental condition. *P5 0.05 versus respective control;
#P5 0.001 versus non-starved wild-type; §P5 0.001 versus starved wild-type. Data were analysed by two-way ANOVA/Bonferroni’s tests.
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p.Asp100Tyr mutation associated with defects in lysosomal
compartments.
ATP6V1A mutations impact on
neuronal pH homeostasis and
neuronal development
In view of the neurodevelopmental phenotype observed in
the four patients carrying de novo heterozygous ATP6V1A
mutations, we investigated whether the effects on lysosomal
homeostasis observed in HEK cells and patient-derived
lymphoblasts were recapitulated in neurons. To address
this question, we transiently expressed ATP6V1A and the
pathogenic mutants thereof in rat hippocampal neuronal
cultures and evaluated intracellular acidic organelles by
LysoTracker staining at the neuronal soma. As shown in
Fig. 6A, neurons overexpressing p.Asp349Asn resulted in a
signiﬁcantly higher LysoTracker staining as compared to
wild-type ATP6V1A-expressing neurons. In contrast,
p.Asp100Tyr ATP6V1A overexpression induced a signiﬁ-
cant loss of LysoTracker staining. Thus, the expression
of the two mutants in neurons precisely phenocopies the
effects observed in cell lines, suggesting that such an alter-
ation in pH and lysosomal homeostasis also occurs in brain
cells.
To investigate cellular correlates of the patients’ neurode-
velopmental delay and explore whether the defects
in LysoTracker signal have an impact on neuronal devel-
opment, we transfected rat hippocampal neurons at 7
DIV and analysed neurite elongation at 10 DIV by Sholl
analysis. The analysis revealed a similar and signiﬁcant loss
of neurite arborization for both p.Asp349Asn- and
p.Asp100Tyr-expressing neurons, indicating that both
pathogenic variants signiﬁcantly affect the outgrowth
and branching of neuronal processes during development
(Fig. 6B).
ATP6V1A mutations affect synapse
formation in primary neurons
In developing neurons, neurite elongation is followed by
synapse formation and stabilization. V-ATPase is a funda-
mental protein component of synaptic vesicles, where it
allows neurotransmitter loading and regulates synaptic
Figure 5 Effects of ATP6V1A mutations on intracellular organelle pH and endo-lysosomal markers in patients’ cells.
(A) Quantification of endocytic organelle pH in lymphoblasts from patients (probands) bearing either p.Asp349Asn (red) or p.Asp100Tyr (blue)
mutation and the respective healthy mothers (black). Individual data and means  SEM of five to six independent measurements are shown.
*P5 0.05; Wilcoxon matched pairs signed rank test. (B) Representative western blot from lymphoblast lysates (30mg) as defined above. LAMP1,
EEA1 and GADPH as loading control is shown. (C) LAMP1 and EEA1 immunoreactivities were quantified by densitometric analysis and
normalized to GADPH. Data are means  SEM from four independent experiments. *P5 0.05; Mann-Whitney U-test.
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Figure 6 Effect of ATP6V1A mutations on pH homeostasis, development and synaptic connectivity in primary hippocampal
neurons. (A) Left: Representative images of rat hippocampal neurons transfected with wild-type (w.t.), Asp349Asn (Asp349Asn) and Asp100Tyr
(Asp100Tyr) ATP6V1A variants at 7 DIV and incubated with LysoTracker (50 nM, 30min) at 10 DIV. Right: LysoTracker fluorescence intensity
was quantified in 31 (wild-type), 28 (Asp349Asn) and 33 (Asp100Tyr) neurons from two independent preparations. Individual data and
means  SEM are shown. *P5 0.05, **P5 0.01 versus wild-type; Kruskall-Wallis/Dunn’s tests. (B) Left: Representative neurite traces of 10 DIV
neurons transfected as in A. Right: Sholl analysis of neurite arborization as a function of distance from the soma. Data are means  SEM of 29–33
neurons for experimental group from three independent preparations. **P5 0.01 versus wild-type; Kruskall-Wallis/Dunn’s tests. (C) Left:
Representative images of hippocampal neurons transfected with wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr
ATP6V1A (Asp100Tyr) variants (top) at 14 DIV and analysed at 17 DIV. White rectangles indicate proximal dendrites shown at high magnification
(bottom). Synaptic boutons were identified by double immunostaining for VGLUT1 (blue) and Homer1 (green). The co-localization panels (col.
points) highlight the double-positive puncta (black), marked by arrowheads, corresponding to bona fide synapses. The merge panels show positive
puncta along transfected branches. Scale bar = 10 mm. Right: Quantitative analysis of synaptic puncta counted on 30-mm branches starting from the
cell body. Data are means  SEM of 27–28 neurons per experimental condition, from three independent preparations. ****P5 0.0001 versus
wild-type; two-way ANOVA/Bonferroni’s tests.
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transmission (Takamori et al., 2006; Takamori, 2016).
Moreover, acidic lysosomes have been recently described
at excitatory postsynaptic sites (Goo et al., 2017;
Padamsey et al., 2017). Accordingly, the expression of
the v-ATPase V1 subunits, ATP6V1A and ATP6V1B2,
was found to increase with in vitro neuronal maturation
and synaptogenesis along with the expression of pre- and
postsynaptic markers (Supplementary Fig. 3A).
To study the effects of ATP6V1A mutants on synapse
formation, we transfected hippocampal neurons at 14
DIV and analysed synapse density at 17 DIV. Excitatory
synaptic contacts were visualized by double immunostain-
ing with the presynaptic marker VGLUT1 and the postsy-
naptic marker Homer1 to identify mature excitatory
synapses unambiguously. Synapse counting at 30 mm dis-
tance from the cell body revealed a signiﬁcant loss of exci-
tatory synaptic connections for p.Asp349Asn and
p.Asp100Tyr overexpressing neurons, suggesting that
both pathogenic variants dramatically impair the formation
and maintenance of excitatory synapses (Fig. 6C). Similar
effects on the density of excitatory synaptic contacts were
observed after treatment of hippocampal neurons with
the lysosomal enzyme inhibitor leupeptin (Supplementary
Fig. 3B).
Discussion
The phenotypic features observed in the four patients re-
ported here can be typically described as developmental
encephalopathy with epilepsy and subsumed as ATP6V1A
encephalopathy, although a larger number of observations
is necessary to reveal the whole phenotypic spectrum.
However, gathering a large series may take a long time
because ATP6V1A mutations are very rare, and have not
emerged before in large cohorts with epileptic and develop-
mental encephalopathies (Allen et al., 2013; Appenzeller
et al., 2014; McRae et al., 2017); we could only identify
four cases through whole exome sequencing studies on
1444 probands from three continents. Querying the
denovo-db, we found only two potential de novo variants
in the coding regions of ATP6V1A, thus further highlight-
ing the rarity of de novo variants in this gene. Pathogenicity
of the de novo p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn
and p.Asp371Gly variants could be established based on
their: (i) occurrence in four patients with a developmental
encephalopathy with epilepsy, the genome-wide statistical
signiﬁcance for missense de novo mutations enrichment;
(ii) absence from publicly available databases; (iii) causing
substitutions at highly evolutionarily conserved amino acid
positions; and (iv) predicted highly damaging consequences
emerging from in silico methods and the high intolerance of
the ATP6V1A gene to variations. Accordingly, structural
modelling allowed to localize the mutated sites in regions
of ATP6V1A responsible for either the proper folding of
the subunit (p.Asp100Tyr), the interaction with the V0 B
subunit (p.Pro27Arg) or the function of the v-ATPase com-
plex (p.Asp349Asn, p.Asp371Gly).
As most causative variations occur with very low allele
frequency within each gene and only account for a small
fraction of epilepsy patients (Myers and Mefford, 2015)
sequencing large cohorts of patients, collected through
large networks and gene-matching tools has higher chances
to ﬁnd multiple affected individuals carrying de novo mu-
tations in the same gene(s) (Hamdan et al., 2017). This
strategy can overcome the challenge to determine whether
the candidate de novo mutations have a causal relationship
with the disease or are found by chance. A statistical frame-
work speciﬁcally developed to address this challenge
(Samocha et al., 2014), and successfully applied to devel-
opmental disorders in previous studies (Lelieveld et al.,
2016; McRae et al., 2017), has also proved instrumental
to demonstrate that ATP6V1A reached genome-wide stat-
istical signiﬁcance for missense de novo mutations enrich-
ment in our cohort.
The Online Mendelian Inheritance in Man (OMIM) cata-
logue contains 59 entries for early infantile epileptic ence-
phalopathies featuring intellectual disability and epilepsy
(https://www.omim.org/entry/308350?search = EIEE&high-
light = eiee) (Supplementary Table 3), caused by mutations
in as many genes, and mentions that similar phenotypes are
also observed in other genetic disorders, highlighting the
extreme genetic heterogeneity underlying this category.
The many genes that have been associated with such
complex developmental epilepsy conditions have revealed
the pathogenic role of mutations affecting diverse molecular
pathways that regulate ion channel functioning, membrane
excitability, synaptic plasticity, neurotransmitter release,
postsynaptic receptors, transporters, cell metabolism, and
many formative steps in early brain development such as
the proliferation and migration of neuronal precursors,
dendritogenesis, synaptogenesis, cell and glial biology
(Guerrini and Noebels, 2014). Our experimental work on
the p.Asp100Tyr and p.Asp349Asn missense substitutions
indicates that ATP6V1A mutations cause functional defects
in v-ATPase physiology with alterations of lysosomal
homeostasis associated with abnormal neuritogenesis and
synaptic density.
The main function of v-ATPase is proton transport and
acidiﬁcation of intracellular organelles, in particular lyso-
somes that have critical requirements for pH. The func-
tional experiments performed on the p.Asp100Tyr
mutation, causing the more severe phenotype, demon-
strated an increased degradation with impaired expression
of ATP6V1A and lower lysosomal abundance. This ﬁnding
was also associated with decreased recruitment of v-ATPase
by autophagosomes under basal and starvation conditions,
suggesting a potential impairment of the autophagic ﬂux, as
recently described in patients with mutations in the acces-
sory v-ATPase subunit ATP6AP2 (Rujano et al., 2017).
Conversely, p.Asp349Asn, which was associated with a
milder phenotype, resulted in decreased endo-lysosomal
pH, with no effects on either expression of the mutant
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protein or lysosomal abundance, pointing to a gain-of-func-
tion effect. This variant slightly impairs v-ATPase trans-
location to autophagosomes under basal, but not
starvation, conditions, suggesting that the formation of
autolysosomes is preserved. These functional ﬁndings
were supported by structural modelling results, predicting
that the p.Asp100Tyr mutation decreases protein stability,
whereas p.Asp349Asn affects the catalytic activity of v-
ATPase.
When modelled in hippocampal neurons, these patho-
genic mutations produced the same signiﬁcant and
divergent effects on lysosomal marker intensity and endo-
lysosomal pH that were observed in cell lines and pro-
bands’ lymphoblasts, reﬂecting their relevance for the
CNS. Moreover, in primary neurons, both p.Asp100Tyr
and p.Asp349Asn mutants induced signiﬁcant and compar-
able defects in dendrite development and excitatory synapse
formation. The neuronal phenotype of both mutants dem-
onstrates a previously unexplored role of the v-ATPase in
the processes of neuronal development and connectivity.
Similarities in changes on synapse formation induced by
the two tested mutations and by leupeptin, a known inhibi-
tor of lysosomal function, suggest an important patho-
physiological role of altered lysosomal homeostasis. This
hypothesis is also supported by recent reports on novel
roles of lysosomes at the synapse for the turnover of syn-
aptic proteins, as well as for the plasticity of dendritic
spines (Goo et al., 2017; Padamsey et al., 2017; Sambri
et al., 2017).
Although the precise molecular mechanisms through
which the described de novo mutations result in a develop-
mental encephalopathy with epilepsy remain to be clariﬁed,
we here propose that alteration in lysosomal homeostasis
may represent a novel pathogenic mechanism for this aetio-
logically heterogeneous group of disorders. Further work is
needed to clarify the role of v-ATPase in brain development
and to precisely establish the cellular signalling pathways
that can be altered by loss of lysosomal homeostasis.
It is often impossible to disentangle whether the develop-
mental or epileptic component is more important in con-
tributing to a patient’s presentation. In the four patients
described here, however, there was good correspondence
between severity of epilepsy and overall neurodevelopmen-
tal impairment, which might suggest either a more severe
brain dysfunction leading to both severe impairment and to
the epileptic encephalopathy or a deleterious effect of early
severe and long-lasting epilepsy on development.
Next generation sequencing studies have demonstrated
that sporadic developmental disorders associated with epi-
lepsy, once considered potentially recessive in nature, often
arise from de novo mutations of dominant genes and that
the same gene can be associated with a broader phenotypic
spectrum than originally believed (Mei et al., 2017). Our
ﬁndings clearly link the ATP6V1A gene with a dominant
form of encephalopathy after two biallelic homozygous
missense mutations of the same gene had been related in
three individuals to cutis laxa, a rare, severe systemic
disorder, leading to early death in one of the patients and
featuring, in addition to generalized skin wrinkling, marked
hypotonia, dysmorphic facial features, cardiac abnormal-
ities, structural brain abnormalities and seizures (Van
Damme et al., 2017). Although comparison between our
patients and the three previously reported with biallelic
ATP6V1A mutations is only partially feasible, there is evi-
dence that biallelic mutations cause a more complex pheno-
type in which severe neurological manifestations are part of
a multi-organ involvement. A number of additional genetic
developmental disorders with epilepsy, including those
related to PRRT2 (Ebrahimi-Fakhari et al., 2015),
TBC1D24 (Balestrini et al., 2016), RELN (Dazzo et al.,
2015) and SLC2A1 (Wang et al., 2000) genes, have been
associated with both autosomal dominant and more severe
recessive phenotypes.
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